- Conditions
- Brain Health, Gestational Hypertension, Alzheimer Disease, Dementia, Cardiovascular Diseases, Pregnancy Related, Pre-Eclampsia
- Interventions
- A combination of various tests and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy on brain health in midlife.
- Diagnostic Test
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 54 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 26, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2117
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 277–288 of 2,117 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Interventions
- Not listed
- Lead sponsor
- Neurogen Biomarking LLC
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Dearborn, Michigan • Flint, Michigan + 2 more
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD) and Related Disorders, Older Adults (60 - 85 Years Old)
- Interventions
- Complex Rhythmic Movement Sequences (CRMS) Sessions
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease
- Interventions
- Lemborexant 10 mg, Lemborexant 20mg, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sleep, Alzheimer Disease
- Interventions
- Suvorexant 20 mg, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
- Interventions
- Tailored Lighting Intervention
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- PMN310, Placebo
- Drug
- Lead sponsor
- ProMis Neurosciences, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Irvine, California • Long Beach, California • Atlantis, Florida + 18 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
- Interventions
- CORT108297, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alzheimer Disease
- Interventions
- Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
- Drug · Combination Product
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- LEADing Dementia End-of-Life Planning Conversations
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- AAV2-BDNF Gene Therapy, AAV2-BDNF Gene Therapy
- Genetic · Biological
- Lead sponsor
- Mark Tuszynski
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • Columbus, Ohio
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.